KZIA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 04:00):

Stats
今日成交量	412 654
平均成交量	854 086
市值	7.12M
EPS	$0 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.00300 (1.06%)

Insider Trading

Date	Person	Action	Amount	type
2013-11-04	Austin Josiah T	Sell	25 400	Sponsored ADRs, each convertible into 25 ordinary shares
2013-11-05	Austin Josiah T	Sell	23 922	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-25	Austin Josiah T	Sell	62 591	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-28	Austin Josiah T	Sell	37 409	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-29	Austin Josiah T	Sell	1 100	Sponsored ADRs, each convertible into 25 ordinary shares

INSIDER POWER
0.00
Last 100 transactions
Buy: 5 568 614 \| Sell: 243 947

音量相关性

長: -0.14 (neutral)

短: 0.25 (neutral)

Signal:(38.972) Neutral

Kazia Therapeutics 相关性

10 最正相关
PPTA	0.912
ACAB	0.901
OCAX	0.901
AVAC	0.898
EZGO	0.897
ALSK	0.894
ESCA	0.891
KVSA	0.888
BCOR	0.883
CNGL	0.882

10 最负相关
VORB	-0.908
PEAR	-0.899
VIEW	-0.897
CFBK	-0.888
GNOG	-0.887
JG	-0.882
BLU	-0.88
HRMY	-0.877
JAN	-0.877
CUTR	-0.872

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kazia Therapeutics 相关性 - 货币/商品

0.18
( neutral )

0.20
( neutral )

0.00
( neutral )

-0.57
( weak negative )

0.21
( neutral )

Kazia Therapeutics 财务报表

Annual	2023
营收:	$555.00
毛利润:	$555.00 (100.00 %)
EPS:	$-1.120

FY	2023
营收:	$555.00
毛利润:	$555.00 (100.00 %)
EPS:	$-1.120

FY	2022
营收:	$25.00
毛利润:	$25.00 (100.00 %)
EPS:	$-1.860

FY	2021
营收:	$15.18M
毛利润:	$0.00 (0.00 %)
EPS:	$-0.716

Financial Reports:

No articles found.

Kazia Therapeutics

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.